Quarter Comparison
Revenue
Operating Income
Net Margin
Income Statement
Balance Sheet
Earnings Release
EX-99.1 2 exhibit991-2026q210xqpr.htm EX-99.1 Document Exhibit 99.1 Absci Reports Business Updates and Second Quarter 2026 Financial and Operating Results Announced positive interim Phase 1 data from the HEADLINE™ trial of ABS-201 Completed $100 million underwritten offering, including $40 million s
EX-99.1 2 exhibit991-2026q210xqpr.htm EX-99.1 Document Exhibit 99.1 Absci Reports Business Updates and Second Quarter 2026 Financial and Operating Results Announced positive interim Phase 1 data from the HEADLINE™ trial of ABS-201 Completed $100 million underwritten offering, including $40 million strategic investment from Eli Lilly & Company Cash, cash equivalents, and marketable securities now sufficient to fund operations into the second half of 2028 VANCOUVER, Wash. and NEW YORK, August 11, 2026 – Absci Corporation (Nasdaq: ABSI), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics designed with generative AI, today reported financial and operating results for the quarter ended June 30, 2026. “The positive Phase 1 interim data from our HEADLINE trial, combined with our strengthened balance sheet and advancing platform, position us well for what comes next,”...
Source
Exhibit EX-99.1
0001672688-26-000134
Filed August 11, 2026 at 8:06 PM UTC. The figures above are from the audited statements, not from this release.